Skip to main content
Trusted advisor to healthcare practitioners · Est. 2016

Practice Operations · For practice managers

FDA Section 361 Compliance Checklist: Biologic Procurement

Published November 16, 2026

Statutory Criteria
4 Core Requirements

Under 21 CFR 1271.10(a), an HCT/P must satisfy all four statutory criteria (minimal manipulation, homologous use, no prohibited combination, and no metabolic systemic dependency) to qualify for Section 361 regulation.

Primary Regulatory Framework
21 CFR Part 1271

The federal regulation governing Human Cells, Tissues, and Cellular and Tissue-Based Products, establishing registration, donor eligibility, and Good Tissue Practice (CGTP) standards.

Required Traceability
Bidirectional Tracking

Clinical practices must maintain lot-level receiving and administration logs capable of tracing any allograft from the source tissue processor directly to the recipient patient chart.

An effective FDA Section 361 compliance checklist for regenerative biologic tissue procurement requires verifying four core criteria under 21 CFR Part 1271.10(a): minimal manipulation, homologous use, absence of systemic effects dependent on living cell metabolic activity (with narrow exceptions), and not combining the tissue with other functional articles. Practice managers must audit processing labs for active FDA Tissue Establishment Registrations, verify donor eligibility documentation, and reject vendors making unsubstantiated clinical claims that push a product into Section 351 drug territory.

The Operational Risk of Biologic Procurement

For medical practice managers overseeing orthopedic, pain management, or aesthetic service lines, sourcing regenerative biologics carries distinct regulatory responsibilities. Unlike standard medical supplies or capital equipment, Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)—such as Wharton's Jelly, amniotic allografts, cord blood, and extracellular vesicles—occupy a tightly scrutinized regulatory framework enforced by the FDA's Center for Biologics Evaluation and Research (CBER).

When a clinic procures and administers an HCT/P that fails to meet Section 361 of the Public Health Service (PHS) Act criteria, the product defaults to regulation under Section 351. Section 351 products are regulated as drugs or biological products, requiring an approved Biologics License Application (BLA) or an active Investigational New Drug (IND) application before they can be legally distributed or administered.

Practice administrators who rely solely on a sales representative's verbal assurances expose their medical directors and business entities to FDA Untitled Letters, Warning Letters, inventory seizures, and liability policy exclusions. Building a standardized, documented procurement workflow is the primary defense against bringing non-compliant tissues into the clinic.

Understanding 21 CFR Part 1271: Section 361 vs. Section 351

To execute an accurate vendor audit, practice managers must understand the statutory boundary between a 361 HCT/P and a 351 biological drug. Under 21 CFR 1271.10(a), an HCT/P is regulated solely under Section 361 if it meets all four of the following criteria:

  1. Minimal Manipulation: For structural tissue (such as amniotic membrane or Wharton's Jelly connective tissue), processing must not alter the original relevant characteristics of the tissue relating to its utility for reconstruction, repair, or replacement. For cells or nonstructural tissues, processing must not alter the relevant biological characteristics of cells or tissues.
  2. Homologous Use Only: The product must perform the same basic function or functions in the recipient as in the donor. Crucially, the FDA evaluates homologous use based on the manufacturer's and distributor's objective intent, which includes labeling, advertising, and oral or written statements by sales representatives.
  3. Not Combined with Another Article: The HCT/P cannot be combined with another article, aside from water, crystalloids, or a sterilizing, preserving, or storage agent, provided the addition does not raise new clinical safety concerns.
  4. No Systemic Effect (with specific exceptions): The HCT/P either does not have a systemic effect and is not dependent upon the metabolic activity of living cells for its primary function, or if it does, it is intended for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use.

If a biologic tissue fails even one of these four pillars—for instance, if an umbilical cord tissue is enzymatically digested to isolate cells, or if a structural allograft is marketed to treat systemic autoimmune diseases—it is not a 361 product. Without an IND or BLA, distributing it is unlawful.

The FDA Section 361 Compliance Checklist for Regenerative Biologic Tissue Procurement

Before onboarding a new tissue bank or distributor, the practice administrator or compliance officer should require the vendor to submit a complete regulatory dossier. Use the following checklist to evaluate both the processing laboratory and the product documentation.

1. Establishment Registration and Accreditations

  • Active FDA FEI Verification: Obtain the processing laboratory's FDA Establishment Identifier (FEI) number and independently verify its status in the FDA's public Human Cell and Tissue Establishment Registration (HCTERS) database. Ensure the registration status is active and lists the specific tissue types you intend to purchase.
  • Clarify Registration vs. Approval: Ensure the vendor does not market their product as "FDA Approved" based on their 361 registration. The FDA does not approve 361 facilities; establishments simply register and list their HCT/Ps. Claiming "FDA approval" for a 361 allograft is a false statement and an immediate compliance red flag.
  • AATB Accreditation: Verify whether the source tissue bank holds active accreditation from the American Association of Tissue Banks (AATB), which establishes rigorous industry standards for tissue recovery, processing, and distribution.
  • State Licensing: Confirm the tissue processor and the distributor hold all required state-level tissue bank or medical device distribution licenses (such as state health department registrations required in Texas, California, New York, and Florida).

2. Processing and Product Qualification Documentation

  • 361 Self-Designation Rationales: Request the manufacturer's written regulatory rationale explaining how the specific product meets the minimal manipulation and homologous use criteria of 21 CFR 1271.10(a).
  • FDA Tissue Reference Group (TRG) Letters: Ask if the manufacturer has submitted the product to the FDA Tissue Reference Group for an informal jurisdictional recommendation. Note that if a vendor claims to have a favorable TRG letter, ask to read the full text; ensure the processing method and intended use described in the letter match the product being sold.
  • Absence of Enzymatic Digestion: For structural birth tissues (like Wharton's Jelly or amniotic membrane), confirm through processing summaries that the tissue has not undergone enzymatic breakdown (such as collagenase digestion) or culture expansion, which the FDA consistently classifies as more than minimal manipulation.

3. Donor Eligibility and Lot-Level Quality Control

  • Summary of Records (Package Insert): Confirm every unit ships with a compliant Summary of Records verifying that the donor was determined eligible based on infectious disease screening and medical history interviews per 21 CFR Part 1271 Subpart C.
  • Communicable Disease Panel: Verify that donor blood samples were tested using FDA-licensed, approved, or cleared donor screening tests for HIV-1/2, Hepatitis B, Hepatitis C, Treponema pallidum (syphilis), HTLV-I/II (where applicable), West Nile Virus, and Zika Virus.
  • Sterility and Endotoxin Testing: Require lot-specific Certificates of Analysis (CoA) demonstrating negative sterility cultures (such as USP <71> standards) and acceptable endotoxin levels prior to lot release.

4. Labeling, Marketing, and Claims Audit

  • Package Insert Review: Examine the official Instructions for Use (IFU). A compliant structural 361 allograft should be labeled solely for homologous functions, such as serving as a protective covering, barrier, or structural cushion/support.
  • Sales Collateral Audit: Review all brochures, slide decks, and patient-facing materials provided by the vendor. Reject any materials that claim the product treats specific diseases (e.g., "cures osteoarthritis," "regenerates cartilage," or "treats neuropathy"), as these constitute non-homologous therapeutic drug claims.
  • Live Cell Claims: Be cautious of vendors heavily marketing high counts of "live, active mesenchymal stem cells" in thawed allogeneic tissues. Because 21 CFR 1271.10(a)(4) restricts allogeneic products that depend on the metabolic activity of living cells for their primary function, marketing metabolic cell activity in unrelated allogeneic donors directly contradicts 361 compliance.

5. Supply Chain, Cold Chain, and Traceability

  • Cold Chain Validation: For cryopreserved tissues, verify the distributor's shipping validation protocols. Determine whether the product requires dry ice or liquid nitrogen vapor shipping, and audit how temperature excursions are monitored during transit.
  • Tissue Tracking Logs: Ensure the vendor provides dual-part tissue tracking labels and an electronic or paper-based recipient tracking system. Under Joint Commission and state standards, the clinic must maintain a bidirectional tracking log linking every unique donor/lot ID to the specific patient chart in the event of an adverse reaction or recall.

Clinical Perspective: Why Compliance Protects the Treating Physician

While practice managers handle vendor vetting and contract negotiations, the clinical ramifications of procurement fall directly on the ordering physician. Whether a practice serves orthopedic patients, operates a pain management clinic, or integrates biologics into aesthetic procedures, the treating physician's medical license and malpractice coverage are tied to the regulatory status of the products they administer.

Most medical malpractice insurance policies contain explicit exclusions for the administration of unapproved drugs or biological products outside of an IRB-approved clinical trial. If a patient experiences an adverse event—such as a sterile inflammatory reaction or a localized infection—following an injection of an improperly classified HCT/P, the malpractice carrier may investigate the product's FDA status. If the carrier determines the product was an unapproved 351 biological drug marketed illegally under the guise of Section 361, coverage for the claim may be contested.

Furthermore, clinicians must ensure their own chart documentation and informed consent forms align with homologous use. Even if a vendor supplies a compliant structural tissue with clean labeling, a physician who documents in the EHR or advertises on the clinic website that they are performing "stem cell therapy to cure joint disease" creates compliance exposure at the practice level. Clinical autonomy requires clear informed consent that accurately describes the structural, homologous nature of the allograft or the autologous nature of point-of-care biologics like PRP.

What This Means for Your Practice

Establishing a compliant biologic procurement pipeline does not require in-house regulatory counsel, provided your administrative team enforces strict vendor qualification standards. Take the following concrete steps before placing your next tissue order:

  1. Build a Vendor Compliance Binder: Create a physical or digital compliance folder for every biologic product in your inventory. Populate it with the processor's active FDA FEI printout, AATB certificate, state licenses, sample CoA, and official package insert.
  2. Audit Your Clinic's Marketing: Review your practice website, social media, and patient intake forms. Remove any inherited vendor language that promises disease-specific cures or refers to off-the-shelf allogeneic tissues as "FDA-approved stem cell therapies."
  3. Standardize Receiving and Tracking SOPs: Train clinical staff to inspect dry ice levels upon delivery, log the lot number and expiration date into a central tissue log before placing the vial into storage, and return recipient tracking cards to the tissue bank promptly.
  4. Partner with Vetted Distributors: Consolidate your procurement through established medical distributors who conduct upstream regulatory due diligence on processing laboratories before adding products to their formulary.

If your practice is evaluating current tissue vendors, expanding into new regenerative service lines, or standardizing your procurement workflows, Dallas Regenerative Solutions provides licensed clinicians and practice administrators with thoroughly vetted biologics and regenerative devices. To review our laboratory compliance documentation or discuss your clinic's supply chain needs, contact our team for an operational consultation.

Frequently asked questions

Does FDA registration mean a regenerative biologic is FDA approved?
No. Under 21 CFR Part 1271, tissue establishments register their facilities and list their Section 361 HCT/Ps with the FDA, which is an administrative requirement rather than a premarket review. Any vendor claiming their Section 361 allograft is 'FDA approved' is misrepresenting their regulatory status and violating federal marketing guidelines.
How can a practice manager verify a tissue bank's FDA status?
Practice managers should request the processing laboratory's FDA Establishment Identifier (FEI) number and search it directly in the FDA's public Human Cell and Tissue Establishment Registration (HCTERS) database. This database confirms whether the facility's registration is active, which tissue types they are registered to process, and when they were last inspected.
What happens if an HCT/P fails to meet all four criteria of Section 361?
If an HCT/P does not meet all four criteria of 21 CFR 1271.10(a)—such as being more than minimally manipulated through enzymatic digestion or marketed for non-homologous systemic uses—it is regulated as a drug or biological product under Section 351. Section 351 products cannot be legally marketed or administered without an approved Biologics License Application (BLA) or an active Investigational New Drug (IND) application.
What donor screening records must accompany every shipment of allograft tissue?
Every compliant HCT/P unit must be accompanied by a Summary of Records confirming that the donor was determined eligible by a responsible person based on medical history interviews and physical assessments. The records must verify negative results on FDA-licensed donor screening tests for relevant communicable disease agents, including HIV-1/2, Hepatitis B, Hepatitis C, and syphilis.
How do a vendor's marketing claims affect a product's Section 361 status?
Under 21 CFR 1271.10(a)(2), homologous use is determined by the manufacturer's and distributor's objective intent, which is established by labeling, advertising, and written or oral statements. Even if a tissue is minimally manipulated in the lab, if the vendor markets it to treat non-homologous conditions or systemic diseases, the product loses its Section 361 eligibility.

Bring regenerative medicine into your practice.

Talk with our team about biologics, devices, or an AI-powered peptide protocol tailored to your patients.

Request Consultation →